Chiron Blood Testing establishes Northern European office in Denmark  

The US biotech company, with businesses in biopharmaceuticals, vaccines and blood testing, establishes a Northern European office in Denmark

Chiron is a biotech company with businesses in biopharmaceuticals, vaccines and blood testing. Chiron has more than 50 products in total, and 2003 revenues reached USD 1.766 billion. Chiron has 5332 employees worldwide, and the global HQ is located in California. Chiron has several distribution centers around the globe, as well as manufacturing facilities in Germany, India and Italy, and R&D facilities in the US and Italy.


Chiron Blood Testing currently has two products on the market: "Procleix System": Nucleic acid testing (NAT) blood-screening assays and instrumentation, and "Immunoassays": Screening and supplemental blood tests for infectious diseases. Additionally, Chiron Blood Testing has just received the CE-mark for the automated system TIGRIS for NAT Blood screening. Chiron Blood Testing has five pipelines for new blood testing products.


Chiron Blood Testing is starting up activities in Denmark. Country manager Ulla Christensen will be responsible for Nordic and Baltic countries, UK and Ireland. Ulla Christensen has 15 years of experience in medical device and pharmaceutical companies. Before joining Chiron, Ulla Christensen held the position of Business Unit Director for Baxter Transfusion Therapies in the Nordics and the Baltic states and Country director for Baxter DK.


Prior to the establishment, Invest in Denmark was in touch with Chiron Blood Testing and has provided the company with information related to starting up activities in Denmark.


For further information, please contact Richard Conroy, EMEA Finance Manager, Chiron Blood Testing,, or Ulla Christensen, Country Manager, or Jens Birk, Invest in Denmark,

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×